An interventional study of Cognitive interview and LCAM intervention in Educational Materials for Genetic Testing, Breast Cancer and Ovarian Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center — 47 open to participants now, 98 under way, 3 of them phase 3. Breast Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 11th largest by planned enrollment of the 156 interventional ones that give a count, is one of 12 that started in 2021, is one of 60 with no phase, reaches primary completion later than 49 of the 97 other live ones, and was the 196th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →47 of the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 4 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Women only
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Women only
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 70+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
253 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 64 · Phase 3 6 · Phase 4 4
First in 1992; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 445 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 51 across the 156 interventional studies, 120 across the 87 observational. Of the 148 that completed or were terminated, 38 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
69 of the studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05316324Phase 3Memorial Sloan Kettering Cancer CenterA Study of the Use of Acellular Dermal Matrix for Breast Reconstruction | 2027-03 |
| NCT03351348Phase 3Memorial Sloan Kettering Cancer CenterBupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control | 2027-11 |
| NCT02301767Memorial Sloan Kettering Cancer CenterMRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study | 2026-11 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT04648904Memorial Sloan Kettering Cancer CenterStudy of a Shortened Radiation Therapy Schedule in People With Breast Cancer | 2026-11 |
Add all 69 to your calendar (.ics) → With an account.
Among the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or multiple genes at the same time. Genetic testing may change the options for treating people with certain types of cancer. For example, some medications are more helpful for the treatment of cancer in people with certain gene changes (mutations).
The researchers are doing this study to develop new educational materials about genetic testing for people who speak different languages and have diverse cultural and educational backgrounds. During the study, the staff will interview participants with diverse cultural and educational backgrounds and ask them to review a sample of the educational materials that have been developed so far. Participants will give their opinions on these materials, and the researchers will use participants' feedback to improve the materials.
The objective of this proposal is to develop, test and evaluate a mainstreaming (LCAM) model for hereditary cancer multigene panel testing (MGPT) among many different types of cancer patients. The central hypothesis is that this LCAM genetic testing model will lead to better patient decision-making, psychosocial, and behavioral outcomes than a traditional model of genetic services represented by our standard-of-care arm. In Phase 1, the researchers will first conduct formative research including transcreation and cognitive interviewing to adapt our existing educational materials (brochure and video) and clinical communication materials (clinic visit summary and family dissemination messaging) for the LCAM model to be useful for patients of many different backgrounds. In Phase 2, the researchers will conduct a randomized clinical trial (RCT) to test and evaluate effects of the LCAM model for hereditary cancer MGPT as compared to standard-of-care among the patients treated at local community hospitals. Patients diagnosed with breast, colorectal, ovarian, pancreatic, or prostate cancer will be offered hereditary cancer MGPT through either: i) standard-of-care wherein in-depth pre-test and post-test genetic counseling are provided via telegenetics (videoconferencing), or ii) LCAM intervention wherein patients receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials. Participants will be followed prospectively and will complete assessments consisting of validated and investigator-designed measures. Phase 2 primary outcomes include genetic test decision satisfaction and genetic counseling satisfaction. Secondary outcomes include additional decision-making, psychosocial, and behavioral outcomes.
For Phase 2, participants will be recruited from our partnering sites, which include Kings County Hospital Center, Queens Cancer Center, Jamaica Hospital Medical Center, and the MSK Ralph Lauren Center for Cancer Care as well via referrals from underserved community sites through the MSK RLCCC network. Study staff will identify eligible patients from review of clinic lists and patient medical records, and will also receive direct study referrals from clinicians located at the partnering sites. Study staff will approach eligible patients in order to describe the study, screen them for eligibility (including assessing language proficiency via self-report and prior experience with cancer genetic counseling/testing), and obtain informed consent and collect their contact information.
The criteria were revised on the registry on Oct 1, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1
Phase 2:
Breast cancer criteria:
Prostate cancer criteria:
Exclusion Criteria:
Phase 1:
Phase 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview. This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2.Phase 2: participants will be randomized to the standard-of-care arm or the LCAM intervention arm.
Other: Cognitive interview
Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics
Behavioral: Standard of care
Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.
Behavioral: LCAM intervention
Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.
Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics
Number of patients who complete the cognitive interview (Phase I)
the number of patients who complete the cognitive interview
Time frame: 1 year
Genetic test decision (Phase II) satisfaction
is measured with the validated Satisfaction with Decisions scale.
Time frame: 6 months
Genetic counseling satisfaction (Phase II)
is measured with the validated Genetic Counseling Satisfaction scale
Time frame: 6 months
Test uptake (Phase II)
the number of patients who complete multigene panel testing
Time frame: 6 months
Knowledge (Phase II)
measured with items from the validated KnowGene scale (scores range from 0 to 6, higher scores indicate greater knowledge)
Time frame: 6 months
Empowerment (Phase II)
measured with the validated Genomics Outcome Scale (scores range from 6 to 30, higher scores indicate greater empowerment)
Time frame: 6 months
Distress (Phase II)
measured with the validated Hospital Anxiety and Depression Scale (total scale scores range from 0 to 42, higher scores indicate greater distress)
Time frame: 6 months
Concerns about genetic testing (Phase II)
measured with the validated Multidimensional Impact of Cancer Risk Assessment questionnaire (total scale scores range from 0 to 95, higher scores indicate greater concerns about genetic testing)
Time frame: 6 months
Family communication (Phase II)
measured with investigator-designed items
Time frame: 6 months
Family cascade testing (Phase II)
the number of first-degree relatives who complete genetic testing
Time frame: 6 months
Intentions to adopt risk management behaviors (Phase II)
measured with items derived from the Behavioral Risk Factor Surveillance System and National Health Interview Survey
Time frame: 6 months
Long term engagement and understanding (Phase II)
measured with investigator-designed items
Time frame: 6 months
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Nov 2021 (actual). Primary completion is estimated for Aug 2027, 69 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 69 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →